Avricore Health CEO Hosts Investor Call December 15th
December 09, 2021 13:51 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) will host a year end update and look ahead discussion by the Company’s CEO...
HealthTab™ to Offer Abbott’s i-STAT Alinity™, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada
November 23, 2021 07:30 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a...
Global Liver Institute Recognized with Two Advocacy Awards for Enduring Contributions and Sustained Service
November 19, 2021 11:58 ET
|
Global Liver Institute
Washington, DC, USA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, November 19, 2021) — Global Liver Institute (GLI), the only patient-led liver health nonprofit operating...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
November 12, 2021 08:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Global Liver Institute Applauds Congresswoman Velázquez and Senator Duckworth for Bold Action on Liver Cancer
October 22, 2021 10:12 ET
|
Global Liver Institute
Washington, DC, USA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
October 15, 2021 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
August 12, 2021 08:05 ET
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
June 17, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Avricore Health Corporate Update Summer 2021
June 09, 2021 08:00 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to provide this corporate update on the Company’s successes in...
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
June 02, 2021 08:05 ET
|
Metacrine, Inc.
Topline data expected to be reported in the fourth quarter of 2021 SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering...